眼眶原发淋巴瘤远期疗效分析

Remote results of radiotherapy for primary orbital lymphoma

目的,分析眼眶原发淋巴瘤的疗效及影响预后的因素。方法,44例经病理证实的眼眶原发淋巴瘤,男女之比为1.6∶1。原发在眼睑结膜的27例,中位年龄44岁,原发在眼眶的17例,中位年龄62岁。双侧同时发病4例。ⅠA期40例,ⅡA期4例。采用常规外照射放射治疗,先用60Coγ射线全眼眶区照射30～35Gy后用60Coγ射线、180kVX线或9MeV电子线进行肿瘤区照射,中位剂量46.5Gy。结果,全部病例的5、10年生存率分别为90.9%、84.5%。眼睑结膜病例的5年生存率明显高于眼眶者(96.3%∶70.6%,P=0.013)。临床分期为Ⅰ期病例生存时间明显长于Ⅱ期者(P=0.000)。结论,眼眶淋巴瘤的复发少、长期预后佳,放射剂量一般不宜超过40Gy。结膜来源的眼睑结膜淋巴瘤与泪腺来源的眼眶淋巴瘤可能是两种临床特点与预后不同的类型。眼眶淋巴瘤是一种容易多发的疾病。放射治疗前肿块手术切除意义不大。

Objective To evaluate treatment effects and to determine the prognostic factors of primary orbital lymphoma. Methods From March 1984 to October 2000, 44 primary orbital lymphoma patients were admitted into our hospital, with 27 males and 17 females. Twenty-seven patients had eyelid or conjunctiva primary, and 17 patients orbit primary. Patient's age ranged from 14 to 86 years (median, 50.5years). According to the Ann Arbor Staging System, there were 40 ⅠEA, 4 ⅡEA lesions. Cobolt-60 γray was given first to the whole orbit to 30-35?Gy followed by 180 kv X-rays or 9 Mev β-beam to the focus to a total dose of 41.0-51.5?Gy (median, 46.5?Gy). Kaplan-Meier method was used to analyze the survival. Log-rank test was used to detect the difference between groups.Results Only 1 patient failed from primary site and 5 patients from distant metastasis after radiotherapy. The 5-year and 10-year cause-specific survival rate were 90.9% and 84.5%, respectively. On univariate and multivariate analyses, eyelid or conjunctiva localization and Ann Arbor stage ⅠEA were independent favorable prognostic factors for survival. The 5-year survival was much higher in eyelid or conjunctiva patients than in orbital ones (96.3% vs 70.6%, P=0.013). The survival time was longer in stage Ⅰ than in stage Ⅱ (P=0.000). Neither the RT dose nor the age or sex influenced the outcome.Conclusions Localized orbital lymphoma can be well controlled with low-dose RT alone. Patients with eyelid or conjunctival localization and stage Ⅰ have better cause-specific survival.